<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xinyuan Lai</style></author><author><style face="normal" font="default" size="100%">Yanying Yu</style></author><author><style face="normal" font="default" size="100%">Wei Xian</style></author><author><style face="normal" font="default" size="100%">Fei Ye</style></author><author><style face="normal" font="default" size="100%">Xiaohui Ju</style></author><author><style face="normal" font="default" size="100%">Yuqian Luo</style></author><author><style face="normal" font="default" size="100%">Huijun Dong</style></author><author><style face="normal" font="default" size="100%">Yi-Hua Zhou</style></author><author><style face="normal" font="default" size="100%">Wenjie Tan</style></author><author><style face="normal" font="default" size="100%">Hui Zhuang</style></author><author><style face="normal" font="default" size="100%">Li, Tong</style></author><author><style face="normal" font="default" size="100%">Xiaoyun Liu</style></author><author><style face="normal" font="default" size="100%">Qiang Ding</style></author><author><style face="normal" font="default" size="100%">Kuanhui Xiang</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication</style></title><secondary-title><style face="normal" font="default" size="100%">iScience </style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://pubmed.ncbi.nlm.nih.gov/35342878/</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">25</style></volume><pages><style face="normal" font="default" size="100%">104136</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">
The global pandemic of COVID-19 caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection confers great threat to public health. Human breast milk is a complex nutritional composition to nourish infants and protect them from different kinds of infectious diseases including COVID-19. Here, we identified that lactoferrin (LF), mucin1 (MUC1), and α-lactalbumin (α-LA) from human breast milk inhibit SARS-CoV-2 infection using a SARS-CoV-2 pseudovirus system and transcription and replication-competent SARS-CoV-2 virus-like-particles (trVLP). In addition, LF and MUC1 inhibited multiple steps including viral attachment, entry, and postentry replication, whereas α-LA inhibited viral attachment and entry. Importantly, LF, MUC1, and α-LA possess potent antiviral activities toward variants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.1 (kappa). Taken together, our study provides evidence that human breast milk components (LF, MUC1, and α-LA) are promising antiviral and potential therapeutic candidates warranting further development for treating COVID-19.

&lt;strong class=&quot;sub-title&quot;&gt;Keywords:&amp;nbsp;&lt;/strong&gt;Biological sciences; Microbiology; Viral microbiology.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>